Volume 10, Issue 4 (12-2022)                   JoMMID 2022, 10(4): 204-207 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sonkar L, Singh R, Sharan J, Verma D. Exacerbation of Activated Latent Tuberculosis Following COVID-19: A Case Report. JoMMID 2022; 10 (4) :204-207
URL: http://jommid.pasteur.ac.ir/article-1-492-en.html
Department of Microbiology, Rohilkhand Medical College and Hospital, Bareilly, 243006, Uttar Pradesh, India
Abstract:   (780 Views)
 While the COVID-19 pandemic affects millions, other infectious diseases might be overlooked. One of these crucial diseases is tuberculosis (TB), a highly infectious bacterial respiratory disease. According to WHO, TB is among the top 10 causes of death globally, with about one-quarter of the world's population infected. COVID-19 has emerged as a potential risk factor for TB in highly prevalent countries because of immunosuppression. This case report highlights a female patient who presented with swelling over the left supraclavicular region, which was very slow in progression. Following COVID-19 infection, a significant increase in swelling within a short time occurred, which was associated with easy fatigability, loss of appetite, generalized weakness, and significant weight loss. Based on investigations, a TB diagnosis was made. Few studies are available regarding the exacerbation of activated latent tuberculosis following COVID-19. Hence, this case report could help in screening and managing such cases.
Full-Text [PDF 564 kb]   (339 Downloads)    
Type of Study: Case Report | Subject: Infectious diseases and public health
Received: 2022/07/26 | Accepted: 2022/10/25 | Published: 2022/12/31

References
1. Friedman A, DeGeorge KC. Reactivation of latent tuberculosis in a COVID-19 patient on corticosteroid treatment. BMJ Case Rep. 2022; 15 (5): e247562. [DOI:10.1136/bcr-2021-247562]
2. Sekaran S, Jagani RP, Waleed MS, Celi CMV, Marzban S. Latent tuberculosis and COVID-19 disease. Discov Rep. 2021; 4 (3): e26. [DOI:10.15190/drep.2021.11]
3. Pozdnyakov A, Jin A, Bader M. Reactivation of Pulmonary Tuberculosis in a Patient With COVID-19. Infect Dis Clin Pract. 2021; 29 (6): e468-e70. [DOI:10.1097/IPC.0000000000001032]
4. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med. 2020; 201 (4): 7-8. [DOI:10.1164/rccm.2014P7]
5. Krajewska J, Krajewski W, Zub K, Zatoński T. COVID-19 in otolaryngologist practice: a review of current knowledge. Eur Arch Otorhinolaryngol. 2020; 277 (7): 1885-97. [DOI:10.1007/s00405-020-05968-y]
6. Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun. 2001; 69 (7): 4195-201. [DOI:10.1128/IAI.69.7.4195-4201.2001]
7. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016; 5 (2): e10. [DOI:10.1038/emi.2016.10]
8. Sheerin D, Abhimanyu, Wang X, Johnson WE, Coussens A. Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis. medRxiv [Preprint]. 2020. [DOI:10.1101/2020.11.25.20236646]
9. Gupta, N, Ish P, Gupta A, Malhotra N, Caminero JA, Singla R, et al. A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis. Eur Respir J. 2020; 56 (5): 2003408. [DOI:10.1183/13993003.03408-2020]
10. Tadolini M, Codecasa LR, García-García J-M, Blanc F-X, Borisov S, Alffenaar J-W, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020; 56 (1): 2001398. [DOI:10.1183/13993003.01398-2020]
11. Ala A, Habtemariam S, Vahdati SS, Rezabakhsh A. Cervical and preauricular lymphadenopathies as atypical manifestations in the setting of COVID-19: a case report. Future Virol. 2022; 17 (4): 215-9. [DOI:10.2217/fvl-2021-0074]
12. AlKhateeb MH, Aziz A, Eltahir M, Elzouki A. Bilateral foot-drop secondary to axonal neuropathy in a tuberculosis patient with co-infection of COVID-19: A case report. Cureus. 2020; 12 (11): e11734. [DOI:10.7759/cureus.11734]
13. Liu C, Yu Y, Fleming J, Wang T, Shen S, Wang Y, et al. Severe COVID-19 cases with a history of active or latent tuberculosis. Int J Tuberc Lung Dis. 2020; 24 (7): 747-9. [DOI:10.5588/ijtld.20.0163]
14. Sarma U, Mishra V, Goel J, Yadav S, Sharma S, Sherawat RK. COVID-19 pneumonia with Delayed Viral Clearance in a patient with Active Drug-resistant Pulmonary Tuberculosis. Indian J Crit Care Med. 2020; 24 (11): 1132-4. [DOI:10.5005/jp-journals-10071-23662]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.